147 related articles for article (PubMed ID: 33209888)
21. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
Liu Y; Wang X; Yang Y
Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional co-activator with PDZ-binding motif overexpression promotes cell proliferation and transcriptional co-activator with PDZ-binding motif deficiency induces cell cycle arrest in neuroblastoma.
Yang L; Huang M; Tan J; Hou J; He J; Wang F; Cui H; Yi L
Oncol Lett; 2017 Jun; 13(6):4295-4301. PubMed ID: 28599430
[TBL] [Abstract][Full Text] [Related]
24. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
[TBL] [Abstract][Full Text] [Related]
25. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
26. The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
Zheng L; Du J; Ge F; Qian M; Yang B; He Q; Weng Q; Zhu H
Pharmazie; 2021 Oct; 76(10):511-514. PubMed ID: 34620281
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis.
Wei Z; Wang Y; Li Z; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Wu Y; Cheng J
J Oral Pathol Med; 2013 Nov; 42(10):747-54. PubMed ID: 23551691
[TBL] [Abstract][Full Text] [Related]
28. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Qian M; Yan F; Wang W; Du J; Yuan T; Wu R; Zhao C; Wang J; Lu J; Zhang B; Lin N; Dong X; Dai X; Dong X; Yang B; Zhu H; He Q
Acta Pharm Sin B; 2021 Dec; 11(12):4008-4019. PubMed ID: 35024322
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
Bendinelli P; Maroni P; Matteucci E; Luzzati A; Perrucchini G; Desiderio MA
Eur J Cancer; 2013 Jul; 49(11):2608-18. PubMed ID: 23566416
[TBL] [Abstract][Full Text] [Related]
30. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
31. Polycystin-2 activity is controlled by transcriptional coactivator with PDZ binding motif and PALS1-associated tight junction protein.
Duning K; Rosenbusch D; Schlüter MA; Tian Y; Kunzelmann K; Meyer N; Schulze U; Markoff A; Pavenstädt H; Weide T
J Biol Chem; 2010 Oct; 285(44):33584-8. PubMed ID: 20833712
[TBL] [Abstract][Full Text] [Related]
32. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
Bhat KP; Salazar KL; Balasubramaniyan V; Wani K; Heathcock L; Hollingsworth F; James JD; Gumin J; Diefes KL; Kim SH; Turski A; Azodi Y; Yang Y; Doucette T; Colman H; Sulman EP; Lang FF; Rao G; Copray S; Vaillant BD; Aldape KD
Genes Dev; 2011 Dec; 25(24):2594-609. PubMed ID: 22190458
[TBL] [Abstract][Full Text] [Related]
34. TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level.
Malik SA; Khan MS; Dar M; Hussain MU; Mudassar S
Cancer Biomark; 2017; 18(4):389-395. PubMed ID: 28128737
[TBL] [Abstract][Full Text] [Related]
35. AMOTL2 interaction with TAZ causes the inhibition of surfactant proteins expression in lung cells.
Lucci V; Di Palma T; D'Ambrosio C; Scaloni A; Zannini M
Gene; 2013 Oct; 529(2):300-6. PubMed ID: 23911299
[TBL] [Abstract][Full Text] [Related]
36. Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner.
Hasegawa T; Sugihara T; Hoshino Y; Tarumoto R; Matsuki Y; Kanda T; Takata T; Nagahara T; Matono T; Isomoto H
Oncol Lett; 2021 Oct; 22(4):703. PubMed ID: 34457058
[TBL] [Abstract][Full Text] [Related]
37. VASN promotes proliferation of laryngeal cancer cells via YAP/TAZ.
Liu H; Kong W; Wen S; Wu J; Yin X; Liu Y
J BUON; 2021; 26(4):1563-1570. PubMed ID: 34565020
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional Coactivator TAZ Negatively Regulates Tumor Suppressor p53 Activity and Cellular Senescence.
Miyajima C; Kawarada Y; Inoue Y; Suzuki C; Mitamura K; Morishita D; Ohoka N; Imamura T; Hayashi H
Cells; 2020 Jan; 9(1):. PubMed ID: 31936650
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
40. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
